Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?

Olivier Gheysens¹, Giorgio Treglia^{2

3

4}, Ahmad Masri⁵, Fabien Hyafil⁶, Sharmila Dorbala^{7

8}

Affiliations

¹ Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc and Institute for Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 10, 1200, Brussels, Belgium. Olivier.gheysens@uclouvain.be.
² Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
³ Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
⁴ Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
⁵ Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA.
⁶ Department of Nuclear Medicine, AP-HP, European Hospital Georges Pompidou, University of Paris-Cité, Paris, France.
⁷ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁸ Cardiac Amyloidosis Program, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 38110712
DOI: 10.1007/s00259-023-06576-8

Editorial

Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?

Olivier Gheysens et al. Eur J Nucl Med Mol Imaging. 2024 Feb.

. 2024 Feb;51(3):691-694.

doi: 10.1007/s00259-023-06576-8.

Authors

Olivier Gheysens¹, Giorgio Treglia^{2

3

4}, Ahmad Masri⁵, Fabien Hyafil⁶, Sharmila Dorbala^{7

8}

Affiliations

¹ Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc and Institute for Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 10, 1200, Brussels, Belgium. Olivier.gheysens@uclouvain.be.
² Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
³ Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
⁴ Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
⁵ Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA.
⁶ Department of Nuclear Medicine, AP-HP, European Hospital Georges Pompidou, University of Paris-Cité, Paris, France.
⁷ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁸ Cardiac Amyloidosis Program, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 38110712
DOI: 10.1007/s00259-023-06576-8

No abstract available

PubMed Disclaimer

Cited by

Collection on molecular imaging in cardiac amyloidosis.
Caobelli F, Rischpler C. Caobelli F, et al. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2163-2164. doi: 10.1007/s00259-024-06739-1. Eur J Nucl Med Mol Imaging. 2024. PMID: 38713297 No abstract available.
2025 Update Consensus of ^99mTc-Pyrophosphate Scintigraphy in the Transthyretin Cardiac Amyloidosis from the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.
Wang SY, Huang YH, Chen YC, Tsai CH, Ko CL, Lin YH, Chen WJ, Yu WC, Hu LH, Hou JU, Su TP, Lee TY, Cheng MF, Wu YW. Wang SY, et al. Acta Cardiol Sin. 2025 Jan;41(1):55-71. doi: 10.6515/ACS.202501_41(1).20241027A. Acta Cardiol Sin. 2025. PMID: 39776923 Free PMC article.

References

1. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2—Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2019;25(11):854–65.
1. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12. - PubMed
1. Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. ^99m Tc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis. Radiology. 2023;306(2):e221082.
1. Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45:1945–55. - PubMed
1. Ahluwalia N, Roshankar G, Draycott L, Jimenez-Zepeda V, Fine N, Chan D, et al. Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis. J Nucl Cardiol. 2023;30(6):2464–76.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?

Affiliations

Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials